Drug Profile

Veverimer - Renibus Therapeutics

Alternative Names: TRC 101; Veverimer

Latest Information Update: 27 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tricida
Developer Renibus Therapeutics; Tricida
Class Chlorinated hydrocarbons; Diamines; Polymers
Mechanism of Action Binding agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Anti-glomerular basement membrane disease
New Molecular Entity Yes

Highest Development Phases

Phase III Metabolic disorders; Renal failure

Most Recent Events

22 Jan 2026 Renibus Therapeutics plans a phase III REVIVE trial for Renal failure and Metabolic acidosis in January 2026 (NCT07355062)
13 Jan 2026 Phase-III clinical trials in Metabolic disorders in USA (PO) (NCT07355062)
13 Jan 2026 Phase-III clinical trials in Renal failure in USA (PO) (NCT07355062)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com